Abcam, ab249548, Anti-Proteasome maturation protein antibody [EPR10177] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Proteasome maturation protein antibody. Carrier free. Suitable for IHC-P, IP, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR10177,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:Flow Cyt (Intra), IP, WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249548 is the carrier-free version of
ab170865
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The proteasome maturation protein also known as POMP or proteassemblin plays an important role in proteasome biogenesis. It is an important factor involved in the assembly of 20S proteasomes serving as a chaperone that regulates the efficient formation of this complex. The mass of the proteasome maturation protein is approximately 21 kDa. It is expressed in various tissues including muscle liver and skin indicating its broad significance in human physiology.
Biological function summary
Proteasome maturation protein assists in the assembly and maturation of the 20S core particle which is central to the proteasome's function. This protein is a critical component of the proteasome assembly chaperone (PAC) complex which includes other chaperones that work together to construct the 20S proteasome. The activity of POMP is fundamental for maintaining cellular homeostasis by managing protein degradation.
Pathways
Proteasome maturation protein plays an important role in the ubiquitin-proteasome pathway a major protein degradation pathway. This process involves tagging defective or unneeded proteins with ubiquitin which are then degraded by the proteasome. The ubiquitin-proteasome pathway coordinates with other pathways such as the NF-kB signaling pathway where it regulates the degradation of inhibitors like IκB facilitating NF-kB activation. By doing so POMP through the proteasome indirectly influences various physiological processes controlled by these pathways.
Alterations in the function of proteasome maturation protein have connections with conditions like cancer and autoimmune diseases. For instance abnormal proteasome activity linked to POMP can contribute to the development of multiple myeloma where proteasome inhibitors are used therapeutically to control protein degradation. Additionally autoimmunity involves irregularities in proteasome functions affecting the proteins processed by the immune system such as the MHC class I molecules. Understanding how POMP contributes to these illnesses can influence treatment strategies leveraging its central role in proteasome assembly and function.